Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

NCT02608268 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02608268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02608268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
November 23, 2015
Completion date
August 30, 2022
Enrollment
252 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies